BerGenBio ASA: Notice of Annual General Meeting

03 Jun 2025 15:55 CEST

Bergen, Norway - 3 June 2025: BerGenBio ASA (OSE:BGBIO) will be holding its
Annual General Meeting virtually on 26 June 2025 at 10:00 hours (CEST).

The notice, registration form and power of attorney are attached to this
release. The notice will be sent to all registered shareholders and the notice
in addition to other attachments are available on the Company's website:
https://www.bergenbio.com/investors/general-meetings/

All shareholders are encouraged to exercise their shareholder rights, either
through advance electronically voting through VPS Investor Services, by using
the enclosed proxy form to provide proxy to the Chairman Anders Tullgren (or the
person he appoints), or to attend the general meeting virtually.
Registration, advance vote or proxy for the Annual General Meeting can be
registered through the company's
website (https://www.bergenbio.com/investors/general-meetings/) or VPS Investor
Service (https://investor.vps.no/garm/auth/login) within 24 June 2025, 23:59
hours (CEST). Virtual participants also need to be logged in to the meeting
before 10:00 hours (CEST) 26 June 2025.

All shareholders will receive a reference number and a pin code required for
registration through the company's website. Reference number and pin code will
be received either by VPS Investor Service or by post depending if the
shareholder is registered as electronical user.
We encourage all shareholders to register as electronical user in VPS.

- END -

Contacts

Olav Hellebø, CEO, BerGenBio ASA
ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

More information:
Access the news on Oslo Bors NewsWeb site

648273_Notice_of_AGM_BerGenBio_ASA_26_June_2025.pdf